TrialScreen and AMRC win SCOPE Site Innovation Award
Orlando, FL | SCOPE 2026
TrialScreen and the Association of Multisite Research Corporations (AMRC) have been named winner of the SCOPE Site Innovation Award, recognizing a partnership that addresses one of the most persistent challenges in clinical research: ensuring people searching for trials can actually reach the right site.
While awareness of clinical trials has improved, connection remains a critical failure point. People are actively searching for clinical trials, but too often encounter missing or incorrect site contact details on public registries. The result is lost referrals, delayed recruitment, and unnecessary frustration for patients, families, and research teams.
"This isn't a technology problem. People are searching, but they're hitting dead ends. If we can't connect people to people, the system fails at the moment it matters most."
Dr Hugo Stephenson, Executive Chair and Co-Founder, TrialScreen
TrialScreen operates the world's largest global search engine of actively recruiting clinical trials, translating public registry data into plain language so people can understand their options before choosing whether to connect.
In a single month, more than 51,300 people visited study pages on TrialScreen across 135 countries. 15,300 people explored trials and screened for eligibility, with over 1,200 individuals connected to their preferred site. Yet registry data shows that, at best, only a fraction of interested people can even make contact with a site, largely due to missing, outdated, or generic contact information.
To address this gap, TrialScreen has partnered with the Association of Multisite Research Corporations (AMRC), which represents 18 multisite clinical research organizations and advocates for its members, working to ensure their advantages are understood and leveraged to advance clinical research.
"This is an important issue. I've been in the industry for decades, mainly focused on patient recruitment. I later had an experience as a patient where the standard of care failed. I called, I emailed, I left voicemail messages, and you know what I got? No answer. I had no confidence that I was contacting the right site, and no way to confirm it. This is a problem."
Jim Kremidas, Executive Director, AMRC
Through the partnership, TrialScreen and AMRC systematically audited and corrected site contact details across AMRC member listings, improving the likelihood that referrals reach research teams.
"This partnership will ensure the long-term quality of listings for AMRC members. That translates directly into more patients reaching the right site and fewer missed opportunities for research teams."
Jim Kremidas, Executive Director, AMRC
Early improvements have already enabled additional patients per month to successfully reach a site. At scale, expansion of this model could unlock hundreds of additional high-intent referrals without increasing site workload.
Rather than launching another awareness campaign, the TrialScreen and AMRC collaboration focuses on existing infrastructure, so that the public can read study information in plain language, make an informed choice before sharing any personal details, and be routed to site teams more reliably.
"Clinical trials bring hope to patients and families. Every patient deserves the chance to reach their preferred study site. Connection is the work."
Dr Hugo Stephenson, Executive Chair and Co-Founder, TrialScreen
TrialScreen and AMRC are inviting sites, site networks, sponsors, and CROs to join this effort by working together to review and correct site contact details so referrals reach real teams, faster. Research teams are encouraged to connect, check their listings, and partner with TrialScreen and AMRC to close the last mile in recruitment.
Partner with us to update your site contact details: contact.trialscreen.com
Media contact
Emma Burrows
Head, Scientific Engagement, TrialScreen
M +61 417 431 376
E emma.burrows@trialscreen.com